These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 32860814)

  • 1. Using phage-assisted continuous evolution (PACE) to evolve human PD1.
    Ye X; Tu M; Piao M; Yang L; Zhou Z; Li Z; Lin M; Yang Z; Zuo Z
    Exp Cell Res; 2020 Nov; 396(1):112244. PubMed ID: 32860814
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Exploring the conformational dynamics of PD1 in complex with different ligands: What we can learn for designing novel PD1 signaling blockers?
    Ponce LF; García-Martínez K; León K; Valiente PA
    Proteins; 2021 Feb; 89(2):141-148. PubMed ID: 32862461
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Macrocyclic Compounds from Ansamycin Antibiotic Class as Inhibitors of PD1-PDL1 Protein-Protein Interaction.
    Patil SP; Yoon SC; Aradhya AG; Hofer J; Fink MA; Enley ES; Fisher JE; Herb MC; Klingos A; Proulx JT; Fedorky MT
    Chem Pharm Bull (Tokyo); 2018; 66(8):773-778. PubMed ID: 30068796
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhibition of PD1:PD-L1 interaction by an E. coli-derived optimized PD1 variant.
    Brand Shwartz M; Assor M; Dotan N; Ratzon E; Cohen E; Ruimi N; Bloch I; Gal M; Yadid I
    Biochem Biophys Res Commun; 2018 Nov; 506(3):731-738. PubMed ID: 30384998
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of PD1/PDL1 Expression and Their Clinicopathologic Association in EBV-associated Lymphoproliferative Disorders in Nonimmunosuppressed Patients.
    Guo L; Bodo J; Durkin L; Hsi ED
    Appl Immunohistochem Mol Morphol; 2019 Feb; 27(2):101-106. PubMed ID: 29084057
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Characterisation of tumour microenvironment and immune checkpoints in primary central nervous system diffuse large B cell lymphomas.
    Alame M; Pirel M; Costes-Martineau V; Bauchet L; Fabbro M; Tourneret A; De Oliveira L; Durand L; Roger P; Gonzalez S; Cacheux V; Rigau V; Szablewski V
    Virchows Arch; 2020 Jun; 476(6):891-902. PubMed ID: 31811434
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Exploiting the Innate Plasticity of the Programmed Cell Death-1 (PD1) Receptor to Design Pembrolizumab H3 Loop Mimics.
    Richaud AD; Zaghouani M; Zhao G; Wangpaichitr M; Savaraj N; Roche SP
    Chembiochem; 2022 Nov; 23(21):e202200449. PubMed ID: 36082509
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Programmed Cell Death Protein 1-PDL1 Interaction Prevents Heart Damage in Chronic
    Fonseca R; Salgado RM; Borges da Silva H; do Nascimento RS; D'Império-Lima MR; Alvarez JM
    Front Immunol; 2018; 9():997. PubMed ID: 29867974
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A combination of PD‑1/PD‑L1 inhibitors: The prospect of overcoming the weakness of tumor immunotherapy (Review).
    Kong X; Lu P; Liu C; Guo Y; Yang Y; Peng Y; Wang F; Bo Z; Dou X; Shi H; Meng J
    Mol Med Rep; 2021 May; 23(5):. PubMed ID: 33760188
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nanobody against PDL1.
    Li S; Jiang K; Wang T; Zhang W; Shi M; Chen B; Hua Z
    Biotechnol Lett; 2020 May; 42(5):727-736. PubMed ID: 32006351
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Recognition of PDL1/L2 by different induced-fit mechanisms of PD1: a comparative study of molecular dynamics simulations.
    Lyu N; Wang K; Zhang F; Qin H; Zhao Y; Wu R; Si Y; Wang L
    Phys Chem Chem Phys; 2020 Jan; 22(3):1276-1287. PubMed ID: 31850422
    [TBL] [Abstract][Full Text] [Related]  

  • 12. PD1 and PDL1 expression in primary central nervous system diffuse large B-cell lymphoma are frequent and expression of PD1 predicts poor survival.
    Four M; Cacheux V; Tempier A; Platero D; Fabbro M; Marin G; Leventoux N; Rigau V; Costes-Martineau V; Szablewski V
    Hematol Oncol; 2017 Dec; 35(4):487-496. PubMed ID: 27966264
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Characterization of a single chain variable fragment of nivolumab that targets PD-1 and blocks PD-L1 binding.
    Shin J; Phelan PJ; Gjoerup O; Bachovchin W; Bullock PA
    Protein Expr Purif; 2021 Jan; 177():105766. PubMed ID: 32987122
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Expanded human NK cells from lung cancer patients sensitize patients' PDL1-negative tumors to PD1-blockade therapy.
    Poznanski SM; Ritchie TM; Fan IY; El-Sayes A; Portillo AL; Ben-Avi R; Rojas EA; Chew MV; Shargall Y; Ashkar AA
    J Immunother Cancer; 2021 Jan; 9(1):. PubMed ID: 33479024
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CTHRC1 and PD‑1/PD‑L1 expression predicts tumor recurrence in prostate cancer.
    Zhou Q; Xiong W; Zhou X; Gao RS; Lin QF; Liu HY; Li JN; Tian XF
    Mol Med Rep; 2019 Nov; 20(5):4244-4252. PubMed ID: 31545446
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immune parameters associated with survival in metaplastic breast cancer.
    Chao X; Liu L; Sun P; Yang X; Li M; Luo R; Huang Y; He J; Yun J
    Breast Cancer Res; 2020 Aug; 22(1):92. PubMed ID: 32811533
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Upregulation of PD‑L1 expression by resveratrol and piceatannol in breast and colorectal cancer cells occurs via HDAC3/p300‑mediated NF‑κB signaling.
    Lucas J; Hsieh TC; Halicka HD; Darzynkiewicz Z; Wu JM
    Int J Oncol; 2018 Oct; 53(4):1469-1480. PubMed ID: 30066852
    [TBL] [Abstract][Full Text] [Related]  

  • 18. PD‑L1/PD‑1 axis serves an important role in natural killer cell‑induced cytotoxicity in osteosarcoma.
    Zhang ML; Chen L; Li YJ; Kong DL
    Oncol Rep; 2019 Nov; 42(5):2049-2056. PubMed ID: 31485666
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Survival and Pulmonary Injury After Neonatal Sepsis: PD1/PDL1's Contributions to Mouse and Human Immunopathology.
    Fallon EA; Chung CS; Heffernan DS; Chen Y; De Paepe ME; Ayala A
    Front Immunol; 2021; 12():634529. PubMed ID: 33746973
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Expression of PD1 and PDL1 as immune-checkpoint inhibitors in mantle cell lymphoma.
    Ameli F; Shajareh E; Mokhtari M; Kosari F
    BMC Cancer; 2022 Aug; 22(1):848. PubMed ID: 35922773
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.